Chapter 28: Principles of Medical Therapy for Glaucoma

Elhusseiny Abdelrahman M, Abboud Ibrahim, Almobayed Amr et al.

This study found chronic PDE-5 inhibitor use was associated with a lower risk of developing glaucoma suspect status or open-angle glaucoma in men, suggesting a potential protective effect.

Mathew, David J, Maurya, Shubham, Ho, Julian et al.

Latanoprost for glaucoma boosts anti-inflammatory lipoxins in the eye, protecting against inflammation and contributing to its IOP-lowering and long-term benefits, independent of IOP.

Cai, Yuting, Zhang, Chenguang, Dang, Pengrui et al.

This smart contact lens monitors eye pressure and automatically releases glaucoma medication when pressure is high, offering a personalized, real-time treatment solution.

Steger Jennifer S, Capó-Aponte José E, Papp Alexandra et al.

Microdrops via Nanodropper showed better IOP lowering, reduced bottle exhaustion, and fewer side effects than conventional drops, potentially improving glaucoma treatment adherence and control.

Singer Michael A, Wykoff Charles C, Riemann Christopher D et al.

The study found that a fluocinolone acetonide implant for DME achieved similar visual and anatomic outcomes to aflibercept, but with fewer total injections, offering a less frequent treatment option.

Cordeiro M Francesca, Oddone Francesco, Mermeklieva Elena Atanasova et al.

This study found a new low-concentration bimatoprost/timolol gel is as effective as standard drops for glaucoma/OHT, offering a safe, comparable treatment option.

Gullon Chloé, Elbany Sandra, Romain-Scelle Nicolas et al.

FAc-implant effectively improved vision and reduced swelling in recurrent inflammatory macular oedema, with limited side effects, offering a valuable long-term treatment option.

Abdelaal Abdelaziz, Abu Serhan Hashem, Alsaadi Mustafa et al.

This meta-analysis found metformin use might modestly reduce glaucoma risk, especially in time-to-event analyses, suggesting a potential preventative strategy for this irreversible blindness.

Marmor Michael F

Hong Yanggang, Mi Yuze, Shu Wanyi et al.

Peker Kubra, Unsal Ayse Ipek Akyuz, Meteoglu Ibrahim et al.

Anti-dopaminergic drugs for diabetic gastroparesis were studied in diabetic rats. They didn't affect eye pressure but reduced retinal angiogenesis markers, suggesting potential for diabetic retinopathy treatment.

Newman-Casey Paula Anne, Niziol Leslie M, Lu Ming-Chen et al.

A coaching program (SEE) significantly improved glaucoma medication adherence and reduced patient distress compared to standard education, offering an evidence-based method to improve glaucoma outcomes.

Yang Sen, Lin Wei-Chun, Kokoyan Annie et al.

This study found preoperative brimonidine nearly tripled the risk of trabeculectomy failure due to high IOP. Clinically, this suggests avoiding brimonidine before trabeculectomy to improve surgical success.

Lupardi Enrico, Ferri Monica, Galzignato Alice et al.

Wirostko Barbara M, Roy Chowdhury Uttio, Brandano Lisa A et al.

QLS-111, a novel potassium channel opener, safely and effectively lowered eye pressure in animals, showing additive benefits with existing glaucoma drugs by reducing episcleral venous pressure, promising a new treatment.

Alfatih Muhammad, Wunardi Christina, Amaral Dillan Cunha et al.

This meta-analysis found preservative-free latanoprost offers similar IOP reduction to preserved latanoprost but causes significantly less ocular surface hyperemia, making it a better option for preservative-sensitive glaucoma patients.

Hamdan Saif A, Zafar Sidra, Nassur Jamie A et al.

Suprachoroidal triamcinolone for uveitic macular edema showed low ocular hypertension incidence (11.8%), consistent with trials. Prior glaucoma/OHT significantly increased OHT risk, guiding patient selection.

Yamamoto Marcus, Hanson Justin, Marin Alejandro I et al.

Suprachoroidal triamcinolone effectively reduced noninfectious cystoid macular edema and improved vision across various causes, with a good safety profile, offering a promising treatment option.

Spindler Jan, Artemiev Dmitri, Pfister Isabel B et al.

Aflibercept 8 mg for diabetic macular edema improved vision and fluid, extending injection intervals in both new and pretreated patients, reducing treatment burden despite some mild inflammation.